AlphaGenome: a New AI Tool to Understand DNA

/in /by

Imagine you have a long string of DNA code, a million letters long. A new AI tool called AlphaGenome reads that code and predicts exactly what it does. It tells you how active genes are, how DNA folds open or closed, where proteins stick to it, and even how far-apart parts of DNA touch each […]

Read more

Nanotech Advancement: Relief from Prostate Cancer Bone Pain on the Horizon

/in , /by

A promising study published this month in Science Advances introduces a promising “neuroimmunotherapy” nanocarrier called LipoNCs@pGSDMB, designed precisely for bone metastases like those in prostate cancer. This tiny, smart drug delivery system activates only in the high-oxidative-stress environment of bone tumors, fusing directly with cancer cell membranes to release its payload straight into the cell’s […]

Read more

SHR-A1921: A Next-Generation TROP2-Targeted Antibody-Drug Conjugate Shows Promise in Prostate Cancer

/in , /by

SHR-A1921, also known as tizetatug rezetecan, represents a significant advancement in targeted cancer therapeutics, specifically designed to exploit TROP2 overexpression in aggressive malignancies including prostate cancer. This novel antibody-drug conjugate (ADC) has demonstrated compelling preclinical activity in prostate cancer models and encouraging early clinical results across multiple solid tumors, positioning it as a potential therapeutic […]

Read more

Phase 1 Trial for DCC-2812 in Metastatic Castration-Resistant Prostate Cancer

/in , , /by

DCC-2812 is a new oral drug designed to fight advanced cancers, especially in the urinary and reproductive systems like kidney, bladder, and prostate cancers. It works by turning on a special stress response inside cancer cells that pushes them past their breaking point, leading to cell death. Cancer cells live in harsh environments with low […]

Read more

Preliminary Data From a Phase 1/2 Trial of PDS01ADC Plus Docetaxel in mCRPC

/in , , , /by

Preliminary results from an ongoing phase 1/2 trial combining docetaxel with the tumor-targeting IL-12 immunocytokine PDS01ADC  (aka M9241) indicate promising early activity in patients with metastatic castration-resistant prostate cancer (mCRPC). The single-arm study, presented at the American Association for Cancer Research special conference on prostate cancer research, enrolled 16 patients with progressive mCRPC, most of […]

Read more

New Phase 3 Trial For BNT324 in Metastatic Castration-Resistant Prostate Cancer

/in , , /by

BNT324 (DB-1311) is rapidly emerging as one of the most promising new agents in metastatic castration-resistant prostate cancer (mCRPC), with a data package that is unusually strong for a first-in-class B7-H3–targeting antibody–drug conjugate and now compelling enough to justify a head‑to‑head Phase 3 trial against docetaxel. The reason it has attracted so much attention is […]

Read more

Actinium‑225 NTSR1‑Targeted Radiopharmaceutical SKL35501

/in , , /by

SKL35501 is an emerging radiopharmaceutical therapy that embodies much of what “next‑generation oncology” is supposed to mean: precise targeting, potent cell kill, and a built‑in companion diagnostic strategy. In January 2026, the US FDA cleared SKL35501 and its imaging partner SKL35502 for a phase 1 Investigational New Drug (IND). SKL35501 originated as FL‑091, a small‑molecule […]

Read more

Recent Discovery on tRNA Halves in Prostate Cancer

/in /by

Tiny pieces of genetic material called tRNA halves play a surprising role in fueling prostate cancer growth, according to new research published in PLOS Biology. These molecules form when normal tRNA, short strands of RNA that help build proteins, get split in half inside cells, especially those driven by male hormones like in prostate cancer. […]

Read more